Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pargluva Development May Be Terminated By Bristol, Merck

This article was originally published in The Pink Sheet Daily

Executive Summary

Regulatory approval and commercial success of the investigational type 2 diabetes drug will require additional clinical trials that could take up to five years to complete, Bristol says.

You may also be interested in...



Merck Research Appointment Reflects Firm's Emphasis On Diabetes, Obesity

Academic Rossetti will have responsibility over scientific direction of Merck's pipeline in the therapeutic areas as VP and franchise head.

Merck Research Appointment Reflects Firm's Emphasis On Diabetes, Obesity

Academic Rossetti will have responsibility over scientific direction of Merck's pipeline in the therapeutic areas as VP and franchise head.

Bristol Joins The Ranks: Firm Bags Pargluva Development

Merck, AstraZeneca and Roche have already stepped out of the dual PPAR development arena.

Related Content

Topics

UsernamePublicRestriction

Register

PS061179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel